Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growth

GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, said price cuts will accelerate volume sales of its medicines in emerging markets led by China as the company extends its reach to less well-off patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.